SE511005C2 - Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom - Google Patents

Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Info

Publication number: SE511005C2
Authority: SE; Sweden
Prior art keywords: treatment; use according; androgenic; substance; gnrh
Prior art date: 1998-07-07

Application number

SE9802438A

Other languages

English (en)

Swedish (sv)

Other versions

SE9802438D0 (sv

SE9802438L (sv

Inventor

Tomas Eriksson

Original Assignee

Laekartjaenster I Vaestsverige

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-07-07

Filing date

1998-07-07

Publication date

1999-07-19

1998-07-07 Application filed by Laekartjaenster I Vaestsverige filed Critical Laekartjaenster I Vaestsverige

1998-07-07 Priority to SE9802438A priority Critical patent/SE511005C2/sv

1998-07-07 Publication of SE9802438D0 publication Critical patent/SE9802438D0/xx

1999-07-05 Priority to AU49494/99A priority patent/AU4949499A/en

1999-07-05 Priority to JP2000557849A priority patent/JP2002519386A/ja

1999-07-05 Priority to PCT/SE1999/001218 priority patent/WO2000001403A1/en

1999-07-05 Priority to EP99933439A priority patent/EP1094830B1/de

1999-07-05 Priority to CA002336656A priority patent/CA2336656A1/en

1999-07-05 Priority to DE69927376T priority patent/DE69927376D1/de

1999-07-05 Priority to AT99933439T priority patent/ATE304862T1/de

1999-07-19 Publication of SE9802438L publication Critical patent/SE9802438L/

1999-07-19 Publication of SE511005C2 publication Critical patent/SE511005C2/sv

2003-06-17 Priority to US10/463,568 priority patent/US20030216293A1/en

Links

238000011282 treatment Methods 0.000 title claims abstract description 37
239000003814 drug Substances 0.000 title claims abstract description 24
239000000126 substance Substances 0.000 title claims abstract description 15
239000000203 mixture Substances 0.000 title claims abstract description 7
208000021384 Obsessive-Compulsive disease Diseases 0.000 title claims abstract description 6
238000004519 manufacturing process Methods 0.000 title claims description 4
NMJREATYWWNIKX-UHFFFAOYSA-N GnRH Chemical class C1CCC(C(=O)NCC(N)=O)N1C(=O)C(CC(C)C)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)CNC(=O)C(NC(=O)C(CO)NC(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C(CC=1NC=NC=1)NC(=O)C1NC(=O)CC1)CC1=CC=C(O)C=C1 NMJREATYWWNIKX-UHFFFAOYSA-N 0.000 title claims 5
210000004556 brain Anatomy 0.000 claims description 14
108010050144 Triptorelin Pamoate Proteins 0.000 claims description 12
VXKHXGOKWPXYNA-PGBVPBMZSA-N triptorelin Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 VXKHXGOKWPXYNA-PGBVPBMZSA-N 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
229960004824 triptorelin Drugs 0.000 claims description 8
238000002347 injection Methods 0.000 claims description 6
239000007924 injection Substances 0.000 claims description 6
MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 claims description 5
102000001307 androgen receptors Human genes 0.000 claims description 4
108010080146 androgen receptors Proteins 0.000 claims description 4
229960002074 flutamide Drugs 0.000 claims description 4
108010037003 Buserelin Proteins 0.000 claims description 3
108010069236 Goserelin Proteins 0.000 claims description 3
BLCLNMBMMGCOAS-URPVMXJPSA-N Goserelin Chemical compound C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 BLCLNMBMMGCOAS-URPVMXJPSA-N 0.000 claims description 3
230000000903 blocking effect Effects 0.000 claims description 3
CUWODFFVMXJOKD-UVLQAERKSA-N buserelin Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](COC(C)(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 CUWODFFVMXJOKD-UVLQAERKSA-N 0.000 claims description 3
ZBVJFYPGLGEMIN-OYLNGHKZSA-N (2s)-n-[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2r)-1-[[(2s)-1-[[(2s)-1-[(2s)-2-[(2-amino-2-oxoethyl)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1h-indol-3-yl)-1-oxopropan-2-yl]amino]-3-( Chemical compound C1=CC=C2C(CC=3C4=CC=CC=C4C=C(C=3O)C(=O)O)=C(O)C(C(O)=O)=CC2=C1.C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 ZBVJFYPGLGEMIN-OYLNGHKZSA-N 0.000 claims description 2
108010000817 Leuprolide Proteins 0.000 claims description 2
229960002719 buserelin Drugs 0.000 claims description 2
229960002913 goserelin Drugs 0.000 claims description 2
229960004338 leuprorelin Drugs 0.000 claims description 2
239000007922 nasal spray Substances 0.000 claims description 2
229940097496 nasal spray Drugs 0.000 claims description 2
238000010255 intramuscular injection Methods 0.000 claims 1
239000007927 intramuscular injection Substances 0.000 claims 1
GFIJNRVAKGFPGQ-LIJARHBVSA-N leuprolide Chemical compound CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 GFIJNRVAKGFPGQ-LIJARHBVSA-N 0.000 claims 1
238000010254 subcutaneous injection Methods 0.000 claims 1
239000007929 subcutaneous injection Substances 0.000 claims 1
229940079593 drug Drugs 0.000 abstract description 21
208000024891 symptom Diseases 0.000 abstract description 16
230000001548 androgenic effect Effects 0.000 description 33
230000000694 effects Effects 0.000 description 20
229940088597 hormone Drugs 0.000 description 20
239000005556 hormone Substances 0.000 description 20
239000008280 blood Substances 0.000 description 19
210000004369 blood Anatomy 0.000 description 19
MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 18
208000030459 obsessive-compulsive personality disease Diseases 0.000 description 18
208000007656 osteochondritis dissecans Diseases 0.000 description 18
XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 description 15
230000015572 biosynthetic process Effects 0.000 description 11
238000000034 method Methods 0.000 description 11
229960003604 testosterone Drugs 0.000 description 9
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 7
102000006771 Gonadotropins Human genes 0.000 description 7
108010086677 Gonadotropins Proteins 0.000 description 7
101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 description 7
230000002280 anti-androgenic effect Effects 0.000 description 7
239000002622 gonadotropin Substances 0.000 description 7
229940035638 gonadotropin-releasing hormone Drugs 0.000 description 7
102000005962 receptors Human genes 0.000 description 7
108020003175 receptors Proteins 0.000 description 7
239000003098 androgen Substances 0.000 description 6
229960000978 cyproterone acetate Drugs 0.000 description 6
UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 6
229940094892 gonadotropins Drugs 0.000 description 6
208000013403 hyperactivity Diseases 0.000 description 6
230000035945 sensitivity Effects 0.000 description 5
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
201000004384 Alopecia Diseases 0.000 description 3
230000001944 accentuation Effects 0.000 description 3
230000001447 compensatory effect Effects 0.000 description 3
210000004907 gland Anatomy 0.000 description 3
208000024963 hair loss Diseases 0.000 description 3
230000003676 hair loss Effects 0.000 description 3
230000009467 reduction Effects 0.000 description 3
230000001568 sexual effect Effects 0.000 description 3
GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 2
206010029897 Obsessive thoughts Diseases 0.000 description 2
206010060862 Prostate cancer Diseases 0.000 description 2
208000000236 Prostatic Neoplasms Diseases 0.000 description 2
206010039792 Seborrhoea Diseases 0.000 description 2
206010000496 acne Diseases 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000002222 downregulating effect Effects 0.000 description 2
230000006872 improvement Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 2
230000037312 oily skin Effects 0.000 description 2
210000000056 organ Anatomy 0.000 description 2
210000001672 ovary Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 2
239000012896 selective serotonin reuptake inhibitor Substances 0.000 description 2
230000004936 stimulating effect Effects 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 1
206010067484 Adverse reaction Diseases 0.000 description 1
206010002942 Apathy Diseases 0.000 description 1
206010010219 Compulsions Diseases 0.000 description 1
206010020112 Hirsutism Diseases 0.000 description 1
206010066364 Hypersexuality Diseases 0.000 description 1
206010062767 Hypophysitis Diseases 0.000 description 1
229940123445 Tricyclic antidepressant Drugs 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
210000004100 adrenal gland Anatomy 0.000 description 1
230000006838 adverse reaction Effects 0.000 description 1
229940025141 anafranil Drugs 0.000 description 1
229940030486 androgens Drugs 0.000 description 1
239000000051 antiandrogen Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
230000003078 antioxidant effect Effects 0.000 description 1
230000033228 biological regulation Effects 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960004606 clomipramine Drugs 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
239000013583 drug formulation Substances 0.000 description 1
230000002124 endocrine Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
230000009123 feedback regulation Effects 0.000 description 1
229960004038 fluvoxamine Drugs 0.000 description 1
CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
238000009472 formulation Methods 0.000 description 1
239000003163 gonadal steroid hormone Substances 0.000 description 1
230000001771 impaired effect Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
238000011866 long-term treatment Methods 0.000 description 1
230000007774 longterm Effects 0.000 description 1
206010025482 malaise Diseases 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000006386 memory function Effects 0.000 description 1
230000007433 nerve pathway Effects 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
238000011458 pharmacological treatment Methods 0.000 description 1
230000007180 physiological regulation Effects 0.000 description 1
210000003635 pituitary gland Anatomy 0.000 description 1
208000020016 psychiatric disease Diseases 0.000 description 1
230000009291 secondary effect Effects 0.000 description 1
230000035936 sexual power Effects 0.000 description 1
239000000243 solution Substances 0.000 description 1
230000003319 supportive effect Effects 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
210000001550 testis Anatomy 0.000 description 1
239000003029 tricyclic antidepressant agent Substances 0.000 description 1
230000002618 waking effect Effects 0.000 description 1
230000004584 weight gain Effects 0.000 description 1
235000019786 weight gain Nutrition 0.000 description 1
229940033942 zoladex Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/09—Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Gastroenterology & Hepatology (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Immunology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Epidemiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

SE9802438A 1998-07-07 1998-07-07 Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom SE511005C2 (sv)

Priority Applications (9)

Application Number	Priority Date	Filing Date	Title
SE9802438A SE511005C2 (sv)	1998-07-07	1998-07-07	Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
AT99933439T ATE304862T1 (de)	1998-07-07	1999-07-05	Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
EP99933439A EP1094830B1 (de)	1998-07-07	1999-07-05	Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
JP2000557849A JP2002519386A (ja)	1998-07-07	1999-07-05	強迫性障害（ＯＣＤ）の治療を目的とするＧｎＲＨ−類似体群の中の少なくとも一種類の物質を含む組成物を使用した治療薬
PCT/SE1999/001218 WO2000001403A1 (en)	1998-07-07	1999-07-05	USE OF COMPOSITION COMPRISING AT LEAST ONE SUBSTANCE WITHIN THE GROUP GnRH-ANALOGUES FOR TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER (OCD)
AU49494/99A AU4949499A (en)	1998-07-07	1999-07-05	Use of composition comprising at least one substance within the group gnrh-analogues for treatment of obsessive-compulsive disorder (ocd)
CA002336656A CA2336656A1 (en)	1998-07-07	1999-07-05	Use of composition comprising at least one substance within the group gnrh-analogues for treatment of obsessive-compulsive disorder (ocd)
DE69927376T DE69927376D1 (de)	1998-07-07	1999-07-05	Verwendung einer zusammensetzung enthaltend zumindest ein gnrh-analoges zur behandlung von zwangsneurotischen erkrankungen
US10/463,568 US20030216293A1 (en)	1998-07-07	2003-06-17	Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
SE9802438A SE511005C2 (sv)	1998-07-07	1998-07-07	Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Publications (3)

Publication Number	Publication Date
SE9802438D0 SE9802438D0 (sv)	1998-07-07
SE9802438L SE9802438L (sv)	1999-07-19
SE511005C2 true SE511005C2 (sv)	1999-07-19

Family

ID=20411995

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SE9802438A SE511005C2 (sv)	1998-07-07	1998-07-07	Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom

Country Status (8)

Country	Link
EP (1)	EP1094830B1 (de)
JP (1)	JP2002519386A (de)
AT (1)	ATE304862T1 (de)
AU (1)	AU4949499A (de)
CA (1)	CA2336656A1 (de)
DE (1)	DE69927376D1 (de)
SE (1)	SE511005C2 (de)
WO (1)	WO2000001403A1 (de)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL147138A0 (en)	2001-12-17	2002-08-14	Yeda Res & Dev	Methods of and pharmaceutical compositions for modulating cell adhesion, migration and extravasation
RS55585B1 (sr)	2006-11-22	2017-06-30	Clinical Research Associates LLC	Postupci za lečenje daunovog sindroma, krhkog x sindroma i autizma

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE514606C2 (sv) *	1998-08-26	2001-03-19	Laekartjaenster I Vaestsverige	Läkemedel innehållande GnRH-analoger för behandling av schizofreni

1998
- 1998-07-07 SE SE9802438A patent/SE511005C2/sv not_active IP Right Cessation
1999
- 1999-07-05 AT AT99933439T patent/ATE304862T1/de not_active IP Right Cessation
- 1999-07-05 AU AU49494/99A patent/AU4949499A/en not_active Abandoned
- 1999-07-05 WO PCT/SE1999/001218 patent/WO2000001403A1/en not_active Ceased
- 1999-07-05 CA CA002336656A patent/CA2336656A1/en not_active Abandoned
- 1999-07-05 EP EP99933439A patent/EP1094830B1/de not_active Expired - Lifetime
- 1999-07-05 DE DE69927376T patent/DE69927376D1/de not_active Expired - Lifetime
- 1999-07-05 JP JP2000557849A patent/JP2002519386A/ja active Pending

Also Published As

Publication number	Publication date
EP1094830B1 (de)	2005-09-21
SE9802438D0 (sv)	1998-07-07
WO2000001403A1 (en)	2000-01-13
AU4949499A (en)	2000-01-24
JP2002519386A (ja)	2002-07-02
CA2336656A1 (en)	2000-01-13
DE69927376D1 (de)	2006-02-02
SE9802438L (sv)	1999-07-19
ATE304862T1 (de)	2005-10-15
EP1094830A1 (de)	2001-05-02

Legal Events

Date	Code	Title	Description
2005-03-01	NUG	Patent has lapsed

Publication	Publication Date	Title
Gillberg	1995	Endogenous opioids and opiate antagonists in autism: brief review of empirical findings and implications for clinicians
Kehlet	1984	The stress response to anaesthesia and surgery: release mechanisms and modifying factors
D'souza et al.	1986	Human synthetic calcitonin gene-related peptide inhibits bone resorption in vitro
Roy et al.	1964	Effects of clomiphene on the physiology of reproduction in the rat
Zakaria et al.	2016	The potential role of melatonin on memory function: lessons from rodent studies
Foegh et al.	1994	Early inhibition of myointimal proliferation by angiopeptin after balloon catheter injury in the rabbit
Fernández-Garza et al.	2025	Growth hormone and aging: a clinical review
EP2197450B1 (de)	2011-12-14	7-keto-dhea zur anwendung in der psychiatrie
SE511005C2 (sv)	1999-07-19	Användning av komposition omfattande minst ett ämne inom gruppen GnRH-analoger för framställning av ett läkemedel för behandling av tvångstanke-tvångshandlingssjukdom
Telegdy et al.	2012	Neurotransmitter-mediated action of an antagonist of growth hormone-releasing hormone on anxiolysis in mice
Peng et al.	2023	Hyperbaric oxygen and treadmill exercise partially prevented bone loss and bone microarchitecture deterioration in ovariectomized rats
JPS63501219A (ja)	1988-05-12	内分泌系ホルモン生成抑制用非経口投与治療組成物および方法
Reznikov et al.	1993	Effects of neuropeptide Y on gonadotropin and prolactin release in normal, castrated or flutamide-treated male rats
SE514606C2 (sv)	2001-03-19	Läkemedel innehållande GnRH-analoger för behandling av schizofreni
US20030216293A1 (en)	2003-11-20	Use of composition comprising at least one substance within the group GnRH-analogues for treatment of obsessive -compulsive disorder (OCD)
Flavin et al.	1983	Corticosteroid abuse—an unusual manifestation of drug dependence
Demling	2007	The use of anabolic agents in catabolic states
Yilmaz et al.	2024	Intracerebroventricular prokineticin 2 infusion may play a role on the hypothalamus-pituitary-thyroid axis and energy metabolism
OA11758A (en)	2005-07-19	Regulation of anaesthesia.
Kang et al.	2023	Analgesic efficacy of median nerve stimulation in mice with chemotherapy-induced peripheral neuropathy via modulation of brain-derived neurotrophic factor expression
JP4903694B2 (ja)	2012-03-28	抗血管形成作用を有する医薬の製造のためのトリフルオロ酢酸カルシウムの使用
Biedermann et al.	1986	Acupuncture and myofascial pain: treatment failure after administration of tricyclic antidepressants
Paunović et al.	1989	The development of dependence to an octapeptide somatostatin analog: contribution to the study of somatostatin analgesia
WO2006088765A1 (en)	2006-08-24	Use of calcitonin and calcitonin-like peptides to treat and prevent multiple sclerosis
RU2696586C1 (ru)	2019-08-05	Гемопротекторное средство